CHF28.40
1.73% today
SIX Swiss Exchange, Dec 30, 05:30 pm CET
ISIN
CH1110760852
Symbol
PPGN
Sector
Industry

PolyPeptide Target price 2024 - Analyst rating & recommendation

PolyPeptide Classifications & Recommendation:

Buy
25%
Hold
50%
Sell
25%

PolyPeptide Price Target

Target Price CHF37.34
Price CHF28.40
Potential
Number of Estimates 3
3 Analysts have issued a price target PolyPeptide 2025 . The average PolyPeptide target price is CHF37.34. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 4 analysts: 1 Analysts recommend PolyPeptide to buy, 2 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the PolyPeptide stock has an average upside potential 2025 of . Most analysts recommend the PolyPeptide stock at Hold.

Sales and Margin forecast 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Revenue Million CHF 311.26 324.81
10.36% 4.35%
EBITDA Margin -3.27% 6.92%
125.40% 311.58%
Net Margin -16.11% -2.72%
673.86% 83.11%

2 Analysts have issued a sales forecast PolyPeptide 2024 . The average PolyPeptide sales estimate is

CHF325m
Unlock
. This is
4.64% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
CHF328m 5.79%
Unlock
, the lowest is
CHF321m 3.49%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2023 CHF311m 10.36%
2024
CHF325m 4.35%
Unlock
2025
CHF385m 18.65%
Unlock
2026
CHF449m 16.59%
Unlock
2027
CHF521m 16.00%
Unlock
2028
CHF582m 11.73%
Unlock

2 Analysts have issued an PolyPeptide EBITDA forecast 2024. The average PolyPeptide EBITDA estimate is

CHF22.5m
Unlock
. This is
87.02% higher
Unlock
than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is
CHF26.9m 124.20%
Unlock
, the lowest is
CHF18.0m 49.84%
Unlock
.

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2023 CHF-10.2m 128.03%
2024
CHF22.5m 320.64%
Unlock
2025
CHF50.1m 122.88%
Unlock
2026
CHF89.0m 77.83%
Unlock
2027
CHF114m 27.87%
Unlock
2028
CHF142m 24.79%
Unlock

EBITDA Margin

2023 -3.27% 125.40%
2024
6.92% 311.58%
Unlock
2025
12.99% 87.72%
Unlock
2026
19.81% 52.50%
Unlock
2027
21.84% 10.25%
Unlock
2028
24.39% 11.68%
Unlock

1 Analyst has issued a net profit forecast PolyPeptide 2024 . The average PolyPeptide net profit estimate is

CHF-8.9m
Unlock
. This is
67.67% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
CHF-8.9m 67.67%
Unlock
, the lowest is
CHF-8.9m 67.67%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2023 CHF-50.1m 733.33%
2024
CHF-8.9m 82.35%
Unlock
2025
CHF11.7m 231.86%
Unlock
2026
CHF39.5m 238.65%
Unlock

Net Margin

2023 -16.11% 673.86%
2024
-2.72% 83.11%
Unlock
2025
3.03% 211.40%
Unlock
2026
8.80% 190.43%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028

Create a premium account to unlock analyst estimates. Learn more

Dec '23 2024
Estimates
Earnings Per Share CHF -1.52 -0.27
733.33% 82.24%
P/E negative
EV/Sales 3.10

1 Analysts have issued a PolyPeptide forecast for earnings per share. The average PolyPeptide <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

CHF-0.27
Unlock
. This is
67.47% higher
Unlock
than earnings per share in the financial year 2023. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
CHF-0.27 67.47%
Unlock
, the lowest is
CHF-0.27 67.47%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2023 CHF-1.52 733.33%
2024
CHF-0.27 82.24%
Unlock
2025
CHF0.35 229.63%
Unlock
2026
CHF1.20 242.86%
Unlock

P/E ratio

Current -34.77 121.61%
2024
-107.71 209.78%
Unlock
2025
81.68 175.83%
Unlock
2026
24.12 70.47%
Unlock

Based on analysts' sales estimates for 2024, the PolyPeptide stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 3.24 39.66%
2024
3.10 4.29%
Unlock
2025
2.61 15.72%
Unlock
2026
2.24 14.23%
Unlock
2027
1.93 13.80%
Unlock
2028
1.73 10.50%
Unlock

P/S ratio

Current 3.07 48.20%
2024
2.93 4.44%
Unlock
2025
2.47 15.72%
Unlock
2026
2.12 14.23%
Unlock
2027
1.83 13.79%
Unlock
2028
1.64 10.50%
Unlock

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today